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Personalized  medicine,  a  discipline  enabled  by  genetic, 
biopharma, diagnostic, and information and communica-
tions (ICT) technologies attempts to tailor disease treat-
ment to individual patients. Personalized medicine is rap-
idly emerging as a state-of-the-art approach to diagnostics 
and  therapeutics  and  is  beginning  to  revolutionize  our 
health care system, promising better medicine for all.
COST – European Cooperation in Science and Technology 
– opened up the field of personalized medicine in 1986 
when, as part of the Biomedicine and Molecular Bioscienc-
es Domain, it sanctioned a research network (aka COST Ac-
tion) to recruit trial subjects based on differences in meta-
bolic capacity (COST Action B1, 1986). Since then, progress 
in technology, along with a growing understanding of in-
dividual susceptibility to disease and treatment effects, has 
led to new concepts in translational science such as the 
Virtual Patient Model. These developments are transform-
ing the way we think about health and disease.
Interdisciplinary methods are facilitating the creation of 
integrated data sets that incorporate biological, chemical, 
and clinical observations through the use of sophisticated 
software and hardware. Mathematics, physics, and chem-
istry are all employed in all aspects of ICT, including gath-
ering data, simulating biological processes, and visualizing 
the system as a whole.
Despite the advances, considerable challenges remain in 
realizing the full potential of personalized medicine, in-
cluding creating a greater awareness among global stake-
holders. Initiatives in Europe, including the UK’s Stratified 
Medicine Innovation Platform, Sweden’s Biobank Program, 
BIOMEDREG in the Czech Republic, and the Munich Bio-
tech Cluster in Germany, are working toward this goal, but 
the efforts are still modest. Our conference aims to high-
light the current activities, along with future possibilities, 
to a broader audience.
Overcoming identified obstacles to making personalized 
medicine more available for patients requires a focus on 
basic, translational, and regulatory science, especially in 
the areas of ethical, legal, and social issues. Improvement in 
patient care must remain a priority throughout the collec-
tion and use of information on an individual patient’s ge-
nome and its downstream products including transcrip-
tomes, proteomes, and metabolomes. This will require 
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between all interested parties with proposals for further 
interdisciplinary  collaborations  involving  mathematics, 
physics, chemistry, and ICT.
Connecting  high-quality  trans-disciplinary  scientists 
through  programs  such  as  COST  can  support  capacity 
building and increase the impact of personalized medi-
cine research on regulatory bodies, decision makers, phar-
maceutical  companies,  and  payers.  Such  collaborations 
could enable breakthrough scientific developments, lead 
to new concepts and products, and contribute to Europe’s 
strength in research and innovation, while reforming the 
health care system.
With this vision in mind, the Chairs of the COST Domains of 
ICT, Biomedicine and Chemistry used their privileged po-
sitions to gather their corresponding scientific communi-
ties together with science policy makers (António Correia 
de Campos MEP – European Parliament, Irene Norstedt – 
European Commission, Stavros Malas – Minister of Health 
of Cyprus) and patients’ associations (Mary Baker – former 
President of European Parkinson Disease Association) for 
the upcoming conference. We believe the three domains 
have succeeded in putting together the necessary stake-
holders to prepare the ground for significant advancement 
in science and technology, and for critical influence on sci-
ence policy.
The success in attracting such a significant and diverse 
cadre of policy makers, patients, and top scientists is the 
full justification for another conference on personalized 
medicine. The  conference  will  take  place  from  June  17 
to 22, 2012 at Golden Bay Beach Hotel in Larnaca, Cyprus 
(http://www.cost.eu/events/pemed).
This event will be not only published in proceedings but 
will also be featured on YouTube.